Inhibition of TNF-α-mediated inflammatory responses by a benzodioxolylacetylamino-linked benzothiazole analog in human fibroblast-like synoviocytes

Biochemical and Biophysical Research Communications

Volumn 408, Issue 4, 2011, Pages 625-629

  Lee, Young Rae ^a   Jin, Guo Hua ^b   Lee, Sang Myeong ^c   Park, Jin Woo ^a   Ryu, Jae Ha ^b   Jeon, Raok ^b   Park, Byung Hyun ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Chonbuk National University   (South Korea)

Author keywords

Inflammation; NF B; RA; Synoviocytes; TNF

Indexed keywords

2 BENZO[1,3]DIOXOL 5 YL N [2 (BENZOTHIAZOL 4 YLOXYMETHYL)PHENYL] N BENZYLACETAMIDE; ANTIINFLAMMATORY AGENT; BENZOTHIAZOLE DERIVATIVE; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SPA 0537; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; FIBROBLAST LIKE SYNOVIOCYTE; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ACETANILIDES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOTHIAZOLES; CELL DIFFERENTIATION; CELLS, CULTURED; FIBROBLASTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; NF-KAPPA B; OSTEOCLASTS; RHEUMATIC FEVER; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956189825     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.073     Document Type: Article

References (38)

1. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874.
2. Simmonds R.E., Foxwell B.M. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatol. (Oxford) 2008, 47:584-590.
3. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
4. Benito M.J., Murphy E., Murphy E.P., van den Berg W.B., FitzGerald O., Bresnihan B. Increased synovial tissue NF-κB1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum. 2004, 50:1781-1787.
5. Hah Y.S., Lee Y.R., Jun J.S., Lim H.S., Kim H.O., Jeong Y.G., Hur G.M., Lee S.Y., Chung M.J., Park J.W., Lee S.I., Park B.H. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 2010, 62:2313-2321.
6. Handel M.L., McMorrow L.B., Gravallese E.M. Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum. 1995, 38:1762-1770.
7. Marok R., Winyard P.G., Coumbe A., Kus M.L., Gaffney K., Blades S., Mapp P.I., Morris C.J., Blake D.R., Kaltschmidt C., Baeuerle P.A. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 1996, 39:583-591.
8. Tomita T., Takeuchi E., Tomita N., Morishita R., Kaneko M., Yamamoto K., Nakase T., Seki H., Kato K., Kaneda Y., Ochi T. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 1999, 42:2532-2542.
9. Campbell I.K., Gerondakis S., O'Donnell K., Wicks I.P. Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. 2000, 105:1799-1806.
10. Lee Y.R., Kweon S.H., Kwon K.B., Park J.W., Yoon T.R., Park B.H. Inhibition of IL-1β-mediated inflammatory responses by the IκBα super-repressor in human fibroblast-like synoviocytes. Biochem. Biophys. Res. Commun. 2009, 378:90-94.
11. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κ B activity through induction of IκB synthesis. Science 1995, 270:286-290.
12. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998, 396:77-80.
13. Jeon K.I., Jeong J.Y., Jue D.M. Thiol-reactive metal compounds inhibit NF-κB activation by blocking IκB kinase. J. Immunol. 2000, 164:5981-5989.
14. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Leflunomide suppresses TNF-induced cellular responses: effects on NF-κB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 2000, 165:5962-5969.
15. Majumdar S., Aggarwal B.B. Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation. J. Immunol. 2001, 167:2911-2920.
16. Jin G.H., Li H., An S., Ryu J.H., Jeon R. Design, synthesis and activity of benzothiazole-based inhibitors of NO production in LPS-activated macrophages. Bioorg. Med. Chem. Lett. 2010, 20:6199-6202.
17. Lee Y.R., Lee J.H., Noh E.M., Kim E.K., Song M.Y., Jung W.S., Park S.J., Kim J.S., Park J.W., Kwon K.B., Park B.H. Guggulsterone blocks IL-1β-mediated inflammatory responses by suppressing NF-κB activation in fibroblast-like synoviocytes. Life Sci. 2008, 82:1203-1209.
18. Firestein G.S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?. Arthritis Rheum. 1996, 39:1781-1790.
19. Youn J., Kim H.Y., Park J.H., Hwang S.H., Lee S.Y., Cho C.S., Lee S.K. Regulation of TNF-α-mediated hyperplasia through TNF receptors, TRAFs, and NF-κB in synoviocytes obtained from patients with rheumatoid arthritis. Immunol. Lett. 2002, 83:85-93.
20. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:578-582.
21. Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy. Arthritis Res. Ther. 2009, 1(1 Suppl.):S1-S12.
22. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
23. McMillan K., Adler M., Auld D.S., Baldwin J.J., Blasko E., Browne L.J., Chelsky D., Davey D., Dolle R.E., Eagen K.A., Erickson S., Feldman R.I., Glaser C.B., Mallari C., Morrissey M.M., Ohlmeyer M.H., Pan G., Parkinson J.F., Phillips G.B., Polokoff M.A., Sigal N.H., Vergona R., Whitlow M., Young T.A., Devlin J.J. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. USA 2000, 97:1506-1511.
24. Patman J., Bhardwaj N., Ramnauth J., Annedi S.C., Renton P., Maddaford S.P., Rakhit S., Andrews J.S. Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:2540-2544.
25. Tseng H.Y., Wu S.H., Huang W.H., Wang S.F., Yang Y.N., Mahindroo N., Hsu T., Jiaang W.T., Lee S.J. Benzothiazolium compounds: novel classes of inhibitors that suppress the nitric oxide production in RAW264.7 cells stimulated by LPS/IFNgamma. Bioorg. Med. Chem. Lett. 2005, 15:2027-2032.
26. Heyninck K., Beyaert R. A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends Biochem. Sci. 2005, 30:1-4.
27. Kang N.I., Yoon H.Y., Lee Y.R., Won M., Chung M.J., Park J.W., Hur G.M., Lee H.K., Park B.H. A20 attenuates allergic airway inflammation in mice. J. Immunol. 2009, 183:1488-1495.
28. Chang M.S., McNinch J., Basu R., Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J. Biol. Chem. 1994, 269:25277-25282.
29. Moriuchi H., Moriuchi M., Fauci A.S. Nuclear factor-κB potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J. Immunol. 1997, 158:3483-3491.
30. Garcia-Vicuna R., Gomez-Gaviro M.V., Dominguez-Luis M.J., Pec M.K., Gonzalez-Alvaro I., Alvaro-Gracia J.M., Diaz-Gonzalez F. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 2004, 50:3866-3877.
31. Koch A.E., Kunkel S.L., Harlow L.A., Mazarakis D.D., Haines G.K., Burdick M.D., Pope R.M., Walz A., Strieter R.M. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin. Invest. 1994, 94:1012-1018.
32. Thornton S., Duwel L.E., Boivin G.P., Ma Y., Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. 1999, 42:1109-1118.
33. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K., Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 2000, 59:455-461.
34. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
35. Xing L., Bushnell T.P., Carlson L., Tai Z., Tondravi M., Siebenlist U., Young F., Boyce B.F. NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 2002, 17:1200-1210.
36. Chaisson M.L., Branstetter D.G., Derry J.M., Armstrong A.P., Tometsko M.E., Takeda K., Akira S., Dougall W.C. Osteoclast differentiation is impaired in the absence of inhibitor of κB kinase α. J. Biol. Chem. 2004, 279:54841-54848.
37. Idris A.I., Libouban H., Nyangoga H., Landao-Bassonga E., Chappard D., Ralston S.H. Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol. Cancer Ther. 2009, 8:2339-2347.
38. Ruocco M.G., Maeda S., Park J.M., Lawrence T., Hsu L.C., Cao Y., Schett G., Wagner E.F., Karin M. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 2005, 201:1677-1687.